Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2013

View Archived Issues

Activity of AXL/c-Met inhibitor CEP-40783 described in vitro and in vivo

Bayer Schering Pharma synthesizes new Mnk1 inhibitors for cancer

Cubist completes acquisition of Optimer Pharmaceuticals

Amgen reports active third quarter 2013

Merck Serono and Selvita enter oncology collaboration targeting metabolic pathways

Merck & Co. plans BLA submission for multivalent HPV vaccine

Intranasal formulation of teriparatide may improve compliance

Shire announces reorganization progress of third quarter 2013

Potent, small-molecule, pyridopyrimidinone inhibitor of schwannoma tumorigenesis described

Development and characterization of a first-in-class bacterial inhibitor

Clinical trials show efficacy of netupitant/palonosetron combination

FDA committee supports approval of simeprevir as part of combination therapy for hepatitis C

FDA approves GE Healthcare's brain imaging drug for Alzheimer's disease and dementia

Five Prime provides update on two antibody candidates entering phase I trials

Pfizer discloses new DGAT2 inhibitors

Novel stem cell microparticles claimed by ReNeuron

New chimeric/humanized antibodies bind to human tau protein

Tissue Therapies files application to conduct pivotal VitroGro ECM trial

NovelMed Therapeutics divulges new monoclonal antibodies

Novel nucleic acid vectors presented by Columbia University

ViiV Healthcare files single-tablet regimen MAA for people living with HIV

Imugene executes sale and purchase agreement to acquire Biolife Science

Zohydro ER approved by the FDA for pain

EMA committee recommends approval of Lundbeck's Brintellix

CHMP issues opinion on compassionate use of Gilead's sofosbuvir for chronic HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...